How does Briviact (brivaracetam) work in the brain?
Briviact’s mechanism of action centers on the way it affects brain signaling through synaptic neurotransmitter release. It binds to synaptic vesicle protein 2A (SV2A), a protein involved in regulating neurotransmitter release from presynaptic nerve terminals. By modulating SV2A, brivaracetam reduces the release of excitatory neurotransmitters, helping to prevent seizure activity.
What is SV2A, and why does binding it matter?
SV2A is found in neurons and plays a role in controlling how neurotransmitters are packaged and released at synapses. When brivaracetam binds SV2A, it changes presynaptic release dynamics, which can dampen hyperexcitable neuronal circuits that contribute to seizures.
Does Briviact target glutamate or other transmitters?
The seizure-preventing effect is tied to reduced release of excitatory neurotransmission. In practical terms, that means brivaracetam shifts synaptic activity away from the “over-firing” state that supports seizure propagation.
How is Briviact’s mechanism different from levetiracetam?
Briviact (brivaracetam) is related to levetiracetam (Keppra) in that both interact with SV2A as part of their antiseizure activity. The key distinction is that brivaracetam has a different binding profile and potency at SV2A, which is why it’s used as an alternative antiepileptic option for some patients.
Why does this mechanism help with seizure control?
Seizures often involve networks of neurons becoming excessively synchronized and firing too readily. By modulating SV2A and lowering excitatory neurotransmitter release, brivaracetam reduces the likelihood that those networks will maintain the hyperexcitable state needed to trigger or spread seizures.